Natera Says Signatera-Negative Immunotherapy Patients Had 93.2% 36-Month Survival vs. 77.9%, With No Significant Difference After Stopping Treatment
Share
Why It Matters
Natera's blood test found patients treated with immunotherapy lived longer overall. This suggests the test helps doctors pick better treatment plans for cancer patients.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.